Hepatitis C Virus Infections in Patients with Hemophilia: Links, Risks and Management

References

• Carmo RA, Martins ML, Chaves DG, Dezanet LNC. Prevalence and risk factors associated with hepatitis C among Brazilian male patients with haemophilia: a long‐term follow‐up. Haemophilia. 2019;25(3):447–455. doi:10.1111/hae.13728
   PubMed Web of Science ®Google Scholar
• Taherkhani R, Farshadpour F. Epidemiology of hepatitis C virus in Iran. World J Gastroenterol. 2015;21(38):10790–10810. doi:10.3748/wjg.v21.i38.10790
   PubMed Web of Science ®Google Scholar
• Blach S, Terrault NA, Tacke F, et al. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7(5):396–415. doi:10.1016/S2468-1253(21)00472-6
   PubMed Web of Science ®Google Scholar
• Lazarus JV, Wiktor S, Colombo M, Thursz M. EASL international liver foundation. Micro-elimination - a path to global elimination of hepatitis C. J Hepatol. 2017;67(4):665–666. doi:10.1016/j.jhep.2017.06.033
   PubMed Web of Science ®Google Scholar
• Jang TY, Lin PC, Huang CI, et al. Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients. PLoS One. 2017;12(6):e0178883. doi:10.1371/journal.pone.0178883
   PubMed Web of Science ®Google Scholar
• Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. Clin Res Hepatol Gastroenterol. 2021;45(3):101596. doi:10.1016/j.clinre.2020.101596
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Hemophilia therapy: the future has begun. Haematologica. 2020;105(3):545–553. doi:10.3324/haematol.2019.232132
   PubMed Web of Science ®Google Scholar
• Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males. Ann Intern Med. 2019;171(8):540–546. doi:10.7326/M19-1208
   PubMed Web of Science ®Google Scholar
• Pipe SW. New therapies for hemophilia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):650–656. doi:10.1182/asheducation-2016.1.650
   PubMed Web of Science ®Google Scholar
• Pereira Guedes T, Garrido M, Kuttner Magalhães R, et al. Long-term follow-up of a Portuguese single-centre cohort of persons with haemophilia and hepatitis C virus infection. PJG. 2021;28(2):79–86. doi:10.1159/000510023
   Web of Science ®Google Scholar
• Rumi MG, Di Marco V, Colombo M. Management of HCV-related liver disease in hemophilia and thalassemia. Semin Liver Dis. 2018;38(2):112–120. doi:10.1055/s-0038-1655774
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C: final update of the series☆. J Hepatol. 2020;73(5):1170–1218. doi:10.1016/j.jhep.2020.08.018
   PubMed Web of Science ®Google Scholar
• Pool JG, Shannon AE. Production of high-potency concentrates of antihemophilic globulin in a closed-bag system. N Engl J Med. 1965;273(27):1443–1447. doi:10.1056/NEJM196512302732701
   PubMed Web of Science ®Google Scholar
• Murphy N, O’Mahony B, Flanagan P, et al. Progression of hepatitis C in the haemophiliac population in Ireland, after 30 years of infection in the pre-DAA treatment era. Haemophilia. 2017;23(5):712–720. doi:10.1111/hae.13244
   PubMed Web of Science ®Google Scholar
• James RC, Mustard CA. Geographic location of commercial plasma donation clinics in the United States, 1980–1995. Am J Public Health. 2004;94(7):1224–1229. doi:10.2105/AJPH.94.7.1224
   PubMed Web of Science ®Google Scholar
• Tobler LH, Busch MP. History of posttransfusion hepatitis. Clin Chem. 1997;43(8 Pt 2):1487–1493. doi:10.1093/clinchem/43.8.1487
   PubMed Web of Science ®Google Scholar
• Klamroth R, Gröner A, Simon TL. Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates: plasma Concentrate Pathogen Safety. Transfusion. 2014;54(5):1406–1417. doi:10.1111/trf.12423
   PubMed Web of Science ®Google Scholar
• Teitel JM. Viral safety of haemophilia treatment products. Ann Med. 2000;32(7):485–492. doi:10.3109/07853890009002024
   PubMed Web of Science ®Google Scholar
• Swiech K, Picanço-Castro V, Covas DT. Production of recombinant coagulation factors: are humans the best host cells? Bioengineered. 2017;8(5):462–470. doi:10.1080/21655979.2017.1279767
   PubMed Web of Science ®Google Scholar
• Nogami K, Shima M. New therapies using nonfactor products for patients with hemophilia and inhibitors. Blood. 2019;133(5):399–406. doi:10.1182/blood-2018-07-820712
   PubMed Web of Science ®Google Scholar
• Isfordink CJ, Erpecum KJ, Valk M, Mauser‐Bunschoten EP, Makris M. Viral hepatitis in haemophilia: historical perspective and current management. Br J Haematol. 2021;195(2):174–185. doi:10.1111/bjh.17438
   PubMed Web of Science ®Google Scholar
• Ghosh K, Ghosh K. Management of haemophilia in developing countries: challenges and options. Indian J Hematol Blood Transfus. 2016;32(3):347–355. doi:10.1007/s12288-015-0562-x
   PubMed Web of Science ®Google Scholar
• Zhang M, Rosenberg PS, Brown DL, et al. Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. Blood. 2006;107(3):892–897. doi:10.1182/blood-2005-07-2781
   PubMed Web of Science ®Google Scholar
• Fransen van de Putte DE, Makris M, Fischer K, et al. Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders. J Hepatol. 2014;60(1):39–45. doi:10.1016/j.jhep.2013.08.010
   PubMed Web of Science ®Google Scholar
• Goedert JJ, Eyster ME, Lederman MM, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood. 2002;100(5):1584–1589.
   PubMed Web of Science ®Google Scholar
• Posthouwer D, Makris M, Yee TT, et al. Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study. Blood. 2007;109(9):3667–3671. doi:10.1182/blood-2006-08-038349
   PubMed Web of Science ®Google Scholar
• Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology. 1997;25(3):754–758. doi:10.1002/hep.510250344
   PubMed Web of Science ®Google Scholar
• Franchini M, Rossetti G, Tagliaferri A, et al. The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders. Blood. 2001;98(6):1836–1841. doi:10.1182/blood.v98.6.1836
   PubMed Web of Science ®Google Scholar
• Prati D, Capelli C, Zanella A, et al. Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection. Gastroenterology. 1996;110(1):178–183. doi:10.1053/gast.1996.v110.pm8536854
   PubMed Web of Science ®Google Scholar
• Minola E, Prati D, Suter F, et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood. 2002;99(12):4588–4591. doi:10.1182/blood-2001-12-0192
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology. 2013;57(1):249–257. doi:10.1002/hep.25800
   PubMed Web of Science ®Google Scholar
• Tagliaferri A, Rivolta GF, Iorio A, et al. Mortality and causes of death in Italian persons with haemophilia, 1990–2007. Haemophilia. 2010;16(3):437–446. doi:10.1111/j.1365-2516.2009.02188.x
   PubMed Web of Science ®Google Scholar
• Orman ES, Fried MW. Hepatitis C viral infection in patients with hemophilia and hemolytic disorders. Clin Liver Dis. 2012;1(3):95–97. doi:10.1002/cld.42
   Google Scholar
• Maor Y, Schapiro JM, Bashari D, Martinowitz U. Survival of hepatitis C-infected haemophilia patients is predicted by presence of cirrhosis but not by anti-viral treatment. Ann Hepatol. 2014;13(6):753–761. doi:10.1016/S1665-2681(19
   PubMed Web of Science ®Google Scholar
• The Data Collection on Adverse Events of Anti-HIV Drugs Study Group. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D Study. Arch Intern Med. 2006;166(15):1632–1641. doi:10.1001/archinte.166.15.1632
   PubMedGoogle Scholar
• Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood. 1994;84(4):1020–1023. doi:10.1182/blood.V84.4.1020.1020
   PubMed Web of Science ®Google Scholar
• Massard J, Ratziu V, Thabut D, et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol. 2006;44:S19–S24. doi:10.1016/j.jhep.2005.11.009
   PubMed Web of Science ®Google Scholar
• Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstål R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol. 2002;37(6):837–842. doi:10.1016/S0168-8278(02)00299-4
   PubMed Web of Science ®Google Scholar
• Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513–521, 521.e1–6. doi:10.1053/j.gastro.2009.09.067
   Web of Science ®Google Scholar
• Tradati F, Colombo M, Mannucci PM, et al. A prospective multicenter study of hepatocellular carcinoma in Italian hemophiliacs with chronic hepatitis C. The study group of the association of Italian hemophilia centers. Blood. 1998;91(4):1173–1177.
   PubMed Web of Science ®Google Scholar
• Santagostino E, Colombo M, Rivi M, et al. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood. 2003;102(1):78–82. doi:10.1182/blood-2002-10-3310
   PubMed Web of Science ®Google Scholar
• Thalappillil A, Ragni MV, Comer DM, Yabes JG. Incidence and risk factors for hepatocellular cancer in individuals with haemophilia: a national inpatient sample study. Haemophilia. 2019;25(2):221–228. doi:10.1111/hae.13668
   PubMed Web of Science ®Google Scholar
• Hassan S, Monahan RC, Mauser-Bunschoten EP, et al. Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001–2018. J Thromb Haemost. 2021;19(3):645–653. doi:10.1111/jth.15182
   PubMed Web of Science ®Google Scholar
• Posthouwer D, Mauser-Bunschoten EP, Fischer K, Makris M. Treatment of chronic hepatitis C in patients with haemophilia: a review of the literature. Haemophilia. 2006;12(5):473–478. doi:10.1111/j.1365-2516.2006.01317.x
   PubMed Web of Science ®Google Scholar
• Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292(23):2839–2848. doi:10.1001/jama.292.23.2839
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438–450. doi:10.1056/NEJMoa040842
   PubMed Web of Science ®Google Scholar
• Franchini M, Mengoli C, Veneri D, Mazzi R, Lippi G, Cruciani M. Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis. J Antimicrob Chemother. 2008;61(6):1191–1200. doi:10.1093/jac/dkn119
   PubMed Web of Science ®Google Scholar
• Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55(9):1350–1359. doi:10.1136/gut.2005.076646
   PubMed Web of Science ®Google Scholar
• Posthouwer D, Plug I, van der Bom JG, Fischer K, Rosendaal FR, Mauser-Bunschoten EP. Hepatitis C infection among Dutch haemophilia patients: a nationwide cross-sectional study of prevalence and antiviral treatment. Haemophilia. 2005;11(3):270–275. doi:10.1111/j.1365-2516.2005.01083.x
   PubMed Web of Science ®Google Scholar
• Xia H, Lu C, Wang Y, et al. Efficacy and safety of direct-acting antiviral therapy in patients with chronic hepatitis C virus infection: a real-world single-center experience in Tianjin, China. Front Pharmacol. 2020;11. doi:10.3389/fphar.2020.00710
   Web of Science ®Google Scholar
• Manns MP, Maasoumy B. Breakthroughs in hepatitis C research: from discovery to cure. Nat Rev Gastroenterol Hepatol. 2022;1–18. doi:10.1038/s41575-022-00608-8
   PubMed Web of Science ®Google Scholar
• Santagostino E, Pol S, Olveira A, et al. Daclatasvir/peginterferon lambda-1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naïve or prior relapsers to peginterferon alfa-2a/ribavirin. Haemophilia. 2016;22(5):692–699. doi:10.1111/hae.12947
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Marcellin P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, −2, and −3 clinical trials. Hepatology. 2015;61(6):1798–1808. doi:10.1002/hep.27724
   PubMed Web of Science ®Google Scholar
• Kish T, Aziz A, Sorio M. Hepatitis C in a new era: a review of current therapies. P T. 2017;42(5):316–329.
   PubMedGoogle Scholar
• Papadopoulos N, Argiana V, Deutsch M. Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management. Ann Gastroenterol. 2018;31(1):35–41. doi:10.20524/aog.2017.0204
   PubMed Web of Science ®Google Scholar
• Stedman CAM, Hyland RH, Ding X, Pang PS, McHutchison JG, Gane EJ. Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. Haemophilia. 2016;22(2):214–217. doi:10.1111/hae.12791
   PubMed Web of Science ®Google Scholar
• Walsh CE, Workowski K, Terrault NA, et al. Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders. Haemophilia. 2017;23(2):198–206. doi:10.1111/hae.13178
   PubMed Web of Science ®Google Scholar
• Hézode C, Colombo M, Bourlière M, et al. Elbasvir/grazoprevir for patients with hepatitis C virus infection and inherited blood disorders: a phase III Study. Hepatology. 2017;66(3):736–745. doi:10.1002/hep.29139
   PubMed Web of Science ®Google Scholar
• Lee HW, Yoo KY, Won JW, Kim HJ. Direct acting antiviral agents in Korean patients with chronic hepatitis C and hemophilia who are treatment-naïve or treatment-experienced. Gut Liver. 2017;11(5):721–727. doi:10.5009/gnl17209
   PubMed Web of Science ®Google Scholar
• Uemura H, Tsukada K, Mizushima D, et al. Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders. PLoS One. 2017;12(10):e0186255. doi:10.1371/journal.pone.0186255
   PubMed Web of Science ®Google Scholar
• Xiao H, Chen J, Wang J, Li J, Yang F, Lu H. Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection. Medicine. 2019;98(30):e16524. doi:10.1097/MD.0000000000016524
   PubMed Web of Science ®Google Scholar
• Mancuso ME, Linari S, Santagostino E, et al. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: a multicenter study. Liver Int. 2020;40(5):1062–1068. doi:10.1111/liv.14337
   PubMed Web of Science ®Google Scholar
• Ackens R, Posthouwer D. Treatment of chronic hepatitis C with direct acting antiviral agents in patients with haemophilia, end-stage liver disease and coinfected with HIV. Haemophilia. 2016;22(3):e223–e225. doi:10.1111/hae.12899
   PubMed Web of Science ®Google Scholar
• Wiegand J, Schiefke I, Stein K, Berg T, Kullig U, Ende K. Interferon-free treatment of chronic hepatitis C virus infection in patients with inherited bleeding disorders. Hamostaseologie. 2017;37(2):127–130. doi:10.5482/HAMO-16-05-0014
   PubMed Web of Science ®Google Scholar
• Mehta R, Kabrawala M, Nandwani S, et al. Daclatasvir-Sofosbuvir for treatment of hepatitis C virus in patients with inherited bleeding disorders. Indian J Gastroenterol. 2017;36(4):332–333. doi:10.1007/s12664-017-0777-x
   PubMed Web of Science ®Google Scholar
• Nagao A, Hanabusa H. Brief report: the impact of ledipasvir/sofosbuvir on HIV-positive and HIV-negative Japanese hemophilia patients with 1, 4, and Mixed-Genotype HCV. J Acquir Immune Defic Syndr. 2017;74(4):418–422. doi:10.1097/QAI.0000000000001271
   PubMed Web of Science ®Google Scholar
• Giouleme O, Paschos P, Katsoula A, Panteliadou K, Vakalopoulou S, Garipidou V. Hepatitis C infection in a Greek population with inherited bleeding disorders. Haemophilia. 2018;24(2):e74–e76. doi:10.1111/hae.13427
   PubMed Web of Science ®Google Scholar
• Maticic M, Lekše A, Kozinc M, et al. Micro-elimination of hepatitis C among patients with congenital bleeding disorders in Slovenia. J Hepatol. 2018;68:S193–S194. doi:10.1016/S0168-8278(18
   Web of Science ®Google Scholar
• Fransen L, D’hondt P, Bielen R, et al. Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: a single‐centre experience. Haemophilia. 2019;25(6):1028–1034. doi:10.1111/hae.13829
   PubMed Web of Science ®Google Scholar
• Sharafi H, Behnava B, Azizi-saraji A, et al. Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders. Virol J. 2021;18(1):199. doi:10.1186/s12985-021-01659-0
   PubMed Web of Science ®Google Scholar
• Ružić M, Rajić N, Fabri M, et al. Implementation of microelimination strategy in eradication of chronic hepatitis C infection in patients with hemophilia in the Northern region of Serbia: is eradication possible? Mediterr J Hematol Infect Dis. 2021;13(1):e2021058. doi:10.4084/MJHID.2021.058
   PubMed Web of Science ®Google Scholar
• Inukai Y, Imai N, Yamamoto K, et al. The influence of hepatitis C virus eradication on hepatocarcinogenesis in patients with hemophilia. Ann Hepatol. 2022;27(1):100545. doi:10.1016/j.aohep.2021.100545
   PubMed Web of Science ®Google Scholar